Celadon Pharmaceuticals PLC
@CeladonPlc
Followers
599
Following
354
Media
150
Statuses
276
Celadon is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and supply of breakthrough cannabis-based medicines.
Joined March 2022
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
Cheney
• 316130 Tweets
Eagles
• 174959 Tweets
Uruguay
• 60662 Tweets
Suárez
• 51307 Tweets
श्री गणेश
• 48849 Tweets
#SmackDown
• 48519 Tweets
Saquon
• 44968 Tweets
Peacock
• 40904 Tweets
Giants
• 40803 Tweets
गणपति बप्पा
• 39104 Tweets
1 Day Left For Avataran Diwas
• 38793 Tweets
Jalen
• 37034 Tweets
Green Bay
• 32218 Tweets
Paraguay
• 28232 Tweets
Philly
• 27990 Tweets
#GaneshChaturthi
• 26876 Tweets
#GBvsPHI
• 26122 Tweets
#GoPackGo
• 16078 Tweets
Lord Ganesha
• 13754 Tweets
#二度と撮れない画像を貼れ
• 13025 Tweets
Jayden Reed
• 11662 Tweets
Fritz
• 11579 Tweets
Jordan Love
• 11108 Tweets
Tiafoe
• 10864 Tweets
BOSSNOEUL Q5 TBNW
• 10783 Tweets
Lucho
• 10740 Tweets
Lynx
• 10416 Tweets
Wisdom & Prosperity
• 10020 Tweets
Pinned Tweet
In a significant development for medical cannabis in the UK, Celadon Pharmaceuticals Plc was proud to be featured on Sky News. Celadon has initiated the first MHRA and NHS REC approved trial of its kind, targeting 5,000 patients with chronic pain. This follows the legalisation of
2
4
8
With today’s milestone GMP registration from the MHRA, Celadon Pharmaceuticals Plc becomes one of a small number of companies globally with the capability to produce EU-GMP grade cannabis product.
#medicalcannabis
#Pharmaceutical
9
49
365
Law changed in 2018 allowing medical cannabis to be prescribed to patients. Since that time Celadon has been working with the UK Home Office and the MHRA to be approved to provide a high-quality and consistent domestic supply of high THC cannabis products.
#CEL
#Medicalcannabis
0
5
18
Jon Robson, CEO and founder of Mamedica, commented: “It’s truly a groundbreaking moment as the UK approves the first trial of its kind."
@BdailyLondon
#CEL
#Medical
#Cannabis
#NHS
1
6
15
Our approved Clinical Trial stands as a remarkable step towards making cannabis-based medicines more widely accessible. It aims to establish a comprehensive data set that will support doctors' prescriptions, and enable potential reimbursement by the NHS and insurance companies.
1
9
11
The UK market is currently reliant on imports from overseas. By investing in production at our state of the art UK facility, we are reducing the sector’s carbon footprint through reduced freight, logistics and transport.
#CEL
#MedicalCannabis
#Pharmaceutical
4
1
11
Celadon look back at 2023:
✅Received Good Manufacturing Practice registration from the UK Medicines and Healthcare products Regulatory Agency
✅Obtained confirmation from the Home Office that it has updated our licence to allow the commercial sale of our high
#THC
product
1
7
11
Celadon successfully completed seven harvests from Phase 1 grow facility, with independent third-party testing of the select test batches confirming high quality, consistent pharmaceutical grade cannabis with high THC profile.
#CEL
#Medicalcannabis
#Pharmaceutical
3
5
12
"Celadon is a pharmaceutical company that operates using cannabinoids, it is not a cannabis company.
It is fundamental we start with the patient first it's an incredible building block."
#CEL
#Medical
#Cannabis
#cannabinoid
#pharmaceutical
#Investor
#Presentation
9
3
9
The results indicate that 29.6 million people, half of the UK’s adult population, have at least one diagnosed medical condition which could be eligible for treatment with medicinal cannabis.
#CEL
#MedicalCannabis
#Pharmaceutical
1
6
10
Great day for Celadon Pharmaceuticals Plc as UK regulators update its cultivation and production licence, enabling the company to commercially supply its cannabis product to the pharmaceutical market.
Read more:
2
8
11
We are pleased to announce our first sales contract win with a leading medicinal cannabis company for a minimum of £3 million worth of product. Celadon has also received multiple further expressions of interest in its pharmaceutical-grade product.
#CEL
#INVESTOR
#PHARMACEUTICALS
1
5
11
Clinical trial will involve up to 5,000 patients and see GP's permitted to prescribe cannabis-based medicines. Once completed NHS will have a proven and cost-effective alternative for managing chronic pain, which we are confident will break down barriers to prescriptions in UK.
1
7
11
Celadon 100,000 sq.ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and manufacturing and an analytical and R&D laboratory. Our Home Office licence allows for commercial supply of its GMP pharmaceutical cannabis product.
2
3
10
Medical cannabis has been legal in the UK since 2018, but the NHS has administered only five prescriptions thus far, compared with a staggering 90,000 via private clinics.
#CEL
#Medicalcannabis
#Pharmaceutical
1
1
9
Celadon has a 100,000 sq ft licenced facility based in the West Midlands in the UK. It is an EU-GMP facility with indoor hydroponic cultivation of high-THC cannabis flower, API extraction and an R&D lab for its drug development programme.
#CEL
#Medical
#Cannabis
#ChronicPain
1
2
9
Celadon successfully complete the internal construction and make strong progress in the fit-out of our Phase 2 cultivation area in 2023. With capacity of our Phase 1 grow facility fully contracted, we have decided to ramp-up our Phase 2 capacity in phases to align with demand.
2
3
8
The UK has an incredible opportunity to improve patients’ lives through cannabis-based medicines for some of the most debilitating conditions, such as
#chronicpain
.
Our CEO James Short talks more about this with City AM. Continue reading at:
0
1
5
🌟 We are thrilled to announce a monumental achievement for Celadon Pharmaceuticals Plc! 🌟
Today, after years of dedication, research, and collaboration, we are proud to ship our first large consignment of medicinal cannabinoid products to the UK market. This marks a
5
6
9
An extremely sad day in the world of cannabinoid research, Professor Raphael Mechoulam has passed away. His dedication and passion for cannabinoids has been felt across the globe and this passion will continue to live on.
Rest in peace.
1
0
9
"After recently signing two contracts with UK pharmaceutical companies for our EU-GMP pharmaceutical cannabis products, and with a strong pipeline of enquiries about new commercial contracts the Company has taken the opportunity to secure £1.0m of additional working capital"
#CEL
0
5
7
Part 1 - Celadon Pharmaceuticals Managing Director Arthur Wakeley interview with
@IanKingSky
@SkyIanKingLive
"Celadon Pharmaceuticals first UK based medical cannabis manufacturer to be granted a Home Office licence to sell its products in the UK."
#CEL
#MedicalCannabis
1
4
8
Celadon is uniquely positioned as a vertically integrated pharmaceutical company to deliver its patient-first mission.
Celadon has raised over £20 million to develop its licenced EU-GMP 100,000 sq ft UK facility to grow high-THC cannabis and extract to API for its medicines.
0
2
6
Part 2 - Celadon Pharmaceuticals Managing Director Arthur Wakeley interview with
@IanKingSky
@SkyIanKingLive
"The big unlock for the UK market for Cannabis based medicines is having domestic production of pharmaceutical grade cultivation and products"
#CEL
#MedicalCannabis
0
6
7
📽️Celadon Pharmaceuticals feature on
@BBCMorningLive
Celadon welcomed
@dr_amoss
into our West Midlands facility to meet CEO James Short to find out about our research into how it could help treat chronic pain.
#CEL
#Medical
#Cannabis
#NHS
#ChronicPain
🩺 The use of cannabis to treat medical conditions is on the rise around the world, including here in the UK.
@dr_amoss
goes to a secret location where a pharmaceutical company legally grows it, to find out about their research into how it could help treat chronic pain.
3
20
25
2
1
7
Celadon’s 100,000 sqft facility is licenced to cultivate high-THC cannabis and to manufacture cannabinoid API to EU-GMP standard using its proprietary extraction technology. Post-legalisation in 2018 in the UK, cannabis-based medicines can be sold under the “specials” framework.
0
3
6
In a groundbreaking move, GP's can now prescribe this medicine to patients participating in the clinical trial alongside specialist doctors.
We believe this development will not only improve patient well-being but also revolutionise the UK market for cannabis-based medicines.
0
4
6
We are pleased to share with you some exciting news about our recent feature on
@DirectorsTalk
.
Read more:
0
2
6
Celadon Pharmaceuticals featured in
@SHARESmag
'5 Small Cap Stars to Buy Today'
…
#CEL
#Medical
#Cannabis
#Shares
#Investing
#investment
#AIM
0
1
6
Celadon has a 100,000sq ft licenced facility based in the West Midlands in the UK. It is an EU-GMP facility with indoor hydroponic cultivation of high-THC cannabis flower, API extraction and an R&D lab for its drug development programme.
#CEL
#Medical
#Cannabis
#NHS
#ChronicPain
0
1
6
Celadon Pharmaceuticals primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism.
#CEL
#Medical
#Cannabis
#ChronicPain
#Cannabinoids
0
2
6
Celadon has a bespoke “track and trace” system throughout the production process, providing complete transparency. Each plant is given a unique QR code, allowing it to be traced from its origins through to the final product.
#CEL
#MedicalCannabis
#uklifesciences
#lifesciences
0
1
6
Celadon's strategy places the Group in a strong position to open up the UK market, having successfully built a strong foundation over the past five years. Successful GMP registration and Home Office licence underpin our ability to supply pharmaceutical-grade product to market.
0
3
6
Celadon’s UK facility licenced by UK regulators to cultivate high-THC cannabis and by MHRA to manufacture cannabinoid API to EU-GMP standard using proprietary technology. Post-legalisation in 2018 in the UK cannabis-based medicines can be sold under the “specials” framework.
#CEL
2
3
6
"With the flexibility that the facility brings to the Group, we continue to confidently pursue the conversion of expressions of interest for Celadon's product into formal sale contracts, and build out the underlying operations required to deliver them."
#CEL
#Medicalcannabis
1
1
6
“This larger clinical trial was designed in collaboration with the MHRA to provide a data set that will enable the potential for prescription and reimbursement by the NHS and insurance companies.”
#CEL
#Medical
#Cannabis
#MedicalCannabis
1
3
5
"Following the signing of our first three supply contracts this year, and imminent delivery of first shipments to our UK customers, we have taken the opportunity to secure £2.0m of additional working capital at an attractive issue price"
#CEL
#Medical
#Cannabis
#investing
0
4
5
Medical cannabis is mostly prescribed for chronic pain, including for patients with multiple sclerosis, neurological and cancer-related pain. It is seen as an alternative to opioids that is less addictive and with other benefits.
#CEL
#Medicalcannabis
3
2
6
Celadon Pharmaceuticals Managing Director Arthur Wakeley features on MediaStorm’s latest podcast.
@MediaStormPod
Chronic pain is a silent pandemic affecting somewhere between 8 and 28 million people in the UK alone.
Listen here:
#CEL
#medicalcannabis
1
2
4
Fantastic conversation about medicinal cannabis on the
@LizEarleWb
show. Host
@LizEarleMe
is joined by author and journalist
@Mary_Biles
who shares her personal journey and expertise.
Tune in below:
0
3
4
Celadon has developed its MHRA conditionally approved chronic pain trial that has the potential to create a robust data set to support reimbursement on the National Health Service in the UK.
Read our trials here:
#CEL
#Medical
#Cannabis
#ChronicPain
1
2
5
Chronic pain is now the most common condition for which medical cannabis is prescribed, according to the UK Medical Cannabis Registry.
#CEL
#MedicalCannabis
#Pharmaceutical
0
2
5
Indoor cultivation optimising yields: Our indoor hydroponic growing system produces a higher yield, less wastage and more careful management of water when compared to outdoor and greenhouse cultivation methods.
#CEL
#MedicalCannabis
#Pharmaceutical
#environmental
1
1
5
"We are delighted to have secured the £7 million credit facility at such an important time in the Company's growth journey. It will support the growth in our operations to meet the increasing demand for Celadon's product." James Short CEO.
#CEL
#Medicalcannabis
#Pharmaceutical
1
1
5
New Canadian research suggests that medicinal cannabis could be a safe and effective way to manage pain in cancer patients.
A study of 358 patients found that THC-CBD balanced products were the most effective at providing pain relief.
Read more:
2
2
5
The UK is the primary driver of new growth in Europe’s medical cannabis market, with sales of medical cannabis greater than expected due to ‘unusually high’ consumption volumes on a per-patient basis.
#CEL
#Medical
#Cannabis
#Pharmaceutical
2
0
5
Celadon continues to receive further expressions of interest in the supply of its pharmaceutical-grade cannabis product, and is currently in discussions to convert these into commercial contracts.
#CEL
#Medical
#Cannabis
#ChronicPain
#Cannabinoids
1
2
5
Celadon uses indoor cultivation hydroponic system in a fully controlled environment. There is no other cultivation facility of this kind in the UK, and the cultivation has been designed to grow to the highest-industry standard of Good Agricultural and Collection Practices (GACP).
0
1
5
Everything at Celadon starts with improving patients’ quality of life. Celadon’s primary focus is chronic pain – a large, unaddressed market (8 million adults in the UK, 50 million in the US, 100 million in Europe), with many problems with existing opioid treatments.
#CEL
0
1
5
April 2nd is World Autism Awareness Day, a day dedicated to increasing understanding and acceptance of individuals with autism and raising awareness about the challenges and unique strengths of those on the autism spectrum.
#worldautismday
0
3
5
Thanks
@OutsourcPharma
for featuring us, following our recent news release. This marks a significant milestone for Celadon Pharmaceuticals, our first international supply of medicinal cannabis products to the USA.
#CEL
#Medical
#Cannabis
#Pharmaceutical
0
0
5
Celadon Pharmaceuticals 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and manufacturing and an analytical and R&D laboratory.
#CEL
#Medical
#Cannabis
#ChronicPain
#Cannabinoids
2
3
5
It's Multiple Sclerosis Awareness Week! Let's join together in raising awareness and understanding of this chronic autoimmune disease. Together, we can support those living with MS and work towards a future without challenges.
#multiplesclerosisawareness
0
1
5
Celadon grows its medical cannabis from an indoor hydroponic facility that is one of the first to gain Good Manufacturing Practice (GMP) from the UK medical regulator.
#CEL
#MedicalCannabis
#Pharmaceutical
2
2
5
James Short, CEO, and Arthur Wakeley, Managing Director of Celadon, share their insights on achieving regulatory compliance for medicinal cannabis in an interview with the
@PharmaReview
.
Read more:
#medicalcannabis
0
3
5
"This indicates that awareness of cannabis medicines is increasing and prescription patient numbers are rising. We hope this momentum will continue, ideally alongside growth in the UK cannabis market – which will help boost the economy and create jobs.”
0
2
4
Eid Mubarak! From all of us at Celadon Pharmaceuticals PLC. Those who are celebrating, we hope you are having a happy and blessed Eid-ul-Fitr. Wishing you and your loved ones peace, health, and joy on this special occasion.
0
1
4
0
1
3
We welcome the initiative by the
@UniofOxford
psychiatry department to launch this major international study into the potential of CBD in treating psychosis. It is great to see universities collaborating to gather evidence on the use of medical cannabis.
0
1
4
The team at Celadon Pharmaceuticals PLC would like to extend our warmest wishes to all our followers celebrating Eid al-Adha. May this festival bring you peace, prosperity, and happiness.
Eid Mubarak from all of us at Celadon Pharmaceuticals PLC!
0
0
4
Celadon Pharmaceuticals CEO James Short and CFO Jonathan Turner presentation
@InvestorMeetCo
Celadon Pharmaceuticals is a UK leader focused on the research, cultivation, manufacturing and supply of breakthrough cannabis-based medicines.
Watch here:
0
2
4
As we acknowledge Brain Injury Awareness Week, let's come together to recognise the struggles faced by individuals who have been affected by brain injuries. We commit to raising awareness and supporting research towards finding a cure.
1
3
4
Lack of Awareness Leaves Millions Without Medical Cannabis Benefits
3
2
4
As an approved Trial, it is believed to be the only one of its kind in the UK, designed to create a data set that will support doctors' prescriptions of cannabis-based medicines, and in time enable potential reimbursement by the NHS and insurance companies.
#CEL
#MedicalCannabis
0
3
4
Celadon Pharmaceuticals is quickly accomplishing milestones like other industry pioneers, and one notable example is GW Pharmaceuticals. GW’s recent acquisition by Jazz Pharmaceuticals for a staggering $7.5 billion USD captured the market’s attention.
1
1
4
Celadon is growing, and we're seeking a talented Human Resources Manager to join our dynamic team.
More details:
#Celadon
#HumanResources
#Recruitment
#CareerOpportunity
#JoinOurTeam
0
1
4
Celadon Pharmaceuticals £7 Million Committed Credit Facility
Celadon enters into a £7 million, two year committed credit facility with a UK-based high net worth investor and current (below 3 per cent) shareholder in the Company.
#CEL
#Medicalcannabis
1
2
4
March is Endometriosis Awareness Month! Join us in spreading awareness about this chronic condition that affects 1 in 10 women, causing pain, irregular bleeding, and fertility problems.
#endometriosisawareness
0
2
4
Celadon Pharmaceuticals Plc will announce its results for the year ended 31 December 2022 on Monday 5 June 2023.
Analyst Briefing: 10.00am, Monday 5 June 2023
Investor Presentation: 3.30pm, Monday 5 June 2023
#CEL
#Medicalcannabis
#Pharmaceutical
1
1
4